Oxurion
Belgium - LeuvenBiotechnology
Focus: Oxurion is a Belgium-based biotechnology company focused on ophthalmic medicines, particularly for diabetic retinopathy and related retinal disorders. The company is newly public (founded 2024) with a pipeline spanning ophthalmology and metabolic indications.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About Oxurion
AI assessmentNot HiringNo open roles listed right now. Follow Oxurion to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
9 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Retinal and Cognitive Dysfunction in Type 2 Diabetes
Retinal FunctionTB-403
Solid TumorsClinical Trials (1)
Help build intelligence for Oxurion
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.